Romvimza Coupons & Savings Card – Discount Prices from $97579.09
Vimseltinib is prescribed for treating tenosynovial giant cell tumors, especially when surgery is not expected to be effective. It is a type of kinase inhibitor that functions by slowing down or halting the growth of specific tumor cells.
Our Romvimza coupons are free to use. You can print the coupon, email it to yourself, or receive the Romvimza coupon via text message. To get your free discount, show the pharmacist your Romvimza savings card which has the discounted coupon price. Use our filters below to edit the prescription box to match your needs. The Romvimza prices will update based on your prescription needs. Above our Romvimza coupons, you can change the location to see pharmacy prices in other areas. Our prescription discount card will update online with the specific pharmacy costs associated with your edits. Be sure to text, email, or print the Romvimza savings card code that you need after editing the prescription box and location field. Show the discount card to your pharmacist before paying.
My prescription
Edit
14MG, Romvimza (30 Capsules)
Select pharmacy
Rite Aid
$97579.09
COUPON PRICE
Walmart
$101684.25
COUPON PRICE
Walgreens
$101695.24
COUPON PRICERomvimza savings card
Show this card to your pharmacistRite Aid
$97579.09
BIN
ID
PCN
GRP
019876
LH706FD089
CHIPPO
LHX
Powered by
Romvimza dosage forms
The average cost for 30 Capsules of Romvimza at 30MG is $100319.53 with a free coupon. This is 72% off the average retail price of $353864.17
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 30MG | 30 Capsules | $97579.09 | $3252.64 |
| 14MG | 30 Capsules | $97579.09 | $3252.64 |
| 20MG | 30 Capsules | $97579.09 | $3252.64 |
Romvimza Side Effects
Itchy skin or tiredness may occur. If either of these effects lasts or gets worse, tell your doctor or pharmacist promptly. People using this medication may have serious side effects. However, you have been prescribed this drug because your doctor has judged that the benefit to you is greater than the risk of side effects. Careful monitoring by your doctor may decrease your risk. Tell your doctor right away if you have any serious side effects, including: signs of liver problems (such as nausea/vomiting that doesn't stop, loss of appetite, stomach/abdominal pain, yellowing eyes/skin, dark urine), swelling around your eyes/eyelids, swelling of arms/legs/feet, numbness/tingling, signs of infection (such as sore throat that doesn't go away, fever, chills). Vimseltinib can commonly cause a rash that is usually not serious. However, you may not be able to tell it apart from a rare rash that could be a sign of a severe reaction. Tell your doctor right away if you develop any rash. A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing. This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist. In the US - Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch. In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Romvimza Interactions
This medication may delay the elimination of certain other drugs from your system, potentially altering their effectiveness. Dofetilide is one such medication that can be impacted.
Romvimza FAQs
What is the mechanism of action of Romvimza?
Romvimza, also known as ramucirumab, is a monoclonal antibody that targets the vascular endothelial growth factor receptor 2 (VEGFR-2). By binding to VEGFR-2, it inhibits the receptor's activation by its natural ligands, which are involved in angiogenesis, the process of new blood vessel formation. This inhibition can reduce the blood supply to tumors, thereby limiting their growth and proliferation.